anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Eligible participants will participate in 2 treatment periods separated by a washout of at least 30 days between investigational product (IP) administrations in each period. Participants will be randomized to 1 of 2 sequences. Participants will be admitted to the clinical unit on day -1 of each period and will be residential for 5 days/4 nights. Participants will receive a single dose of isavuconazonium sulfate IV solution via NG tube (test formulation) or isavuconazonium sulfate capsules for oral administration (i.e., oral capsules administered to nonintubated participants) (reference formulation) under fasting conditions on day 1 of each period. Participants are to remain semirecumbent and avoid lying on either the left or right side for 4 hours postdose. Correct placement of the NG tube will be confirmed using X-ray radiography. Pharmacokinetic samples will be collected predose on day 1 of each period and at multiple time points postdose. Standard safety and tolerability assessments will be conducted. Participants will be discharged from the clinical unit on day 4 of each period on the condition that all required assessments have been performed and that there are no medical reasons for a longer stay in the clinical unit. Participants will return for ambulatory visits to collect pharmacokinetic samples on days 8, 11, 15 and 21 of each period.

The study will be completed with an end-of-study visit (ESV). The ESV will take place 5 to 9 days after day 21 of period 2 or at early discontinuation from the study.
In the field of drug discovery, there is a substantial challenge in seeking out chemical structures that possess desirable pharmacological, toxicological, and pharmacokinetic properties. Complications arise when drugs interfere with the functioning of cardiac ion channels, leading to serious cardiovascular consequences. The discontinuation and removal of numerous approved drugs from the market or at late development stages in the pipeline due to such inhibitory effects further highlight the urgency of addressing this issue. Consequently, the early prediction of potential blockers targeting cardiac ion channels during the drug discovery process is of paramount importance. This study introduces a deep learning framework that computationally determines the cardiotoxicity associated with the voltage-gated potassium channel (hERG), the voltage-gated calcium channel (Cav1.2), and the voltage-gated sodium channel (Nav1.5) for drug candidates. The predictive capabilities of three feature representations─molecular fingerprints, descriptors, and graph-based numerical representations─are rigorously benchmarked. Additionally, a novel training and evaluation data set framework is presented, enabling predictive model training of drug off-target cardiotoxicity using a comprehensive and large curated data set covering these three cardiac ion channels. To facilitate these predictions, a robust and comprehensive small molecule cardiotoxicity prediction tool named CToxPred has been developed. It is made available as open source under the permissive MIT license at https://github.com/issararab/CToxPred.
The present invention belongs to the technical field of nanoparticle, and particularly relates to a mannose-modified thiolated chitosan quaternary ammonium salt nanoparticle, a preparation method and application thereof. The nanoparticle of the invention is generated through polyelectrolyte effect between mannose-modified thiolated chitosan quaternary ammonium salt with positive charges and mannose-modified thiolated chitosan quaternary ammonium salt with negative charges. Simultaneously the nanoparticle loads protein peptide medicine or nucleic acid medicine with negative charges, wherein the mannose-modified thiolated chitosan quaternary ammonium salt is obtained from amino-groups of the chitosan through quaternizing, mannose ligand and sulfhydrylation modification successively. The nanoparticle has the following advantages: no requirement for organic solvent in preparation process, and effectively improved medicine stability. The nanoparticle can actively target intestinal epithelial cells, M cells and macrophages. Intestinal absorption for the oral medicine and transfection efficiency of the nucleic acid medicine are effectively improved. The effect of the mannose-modified thiolated chitosan quaternary ammonium salt nanoparticle is much better than that of the prior-art chitosan nanoparticle.
Level 1: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral 5-aminosalicylic acid (5-ASA) 2 g/day. Level 2: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral azathioprine (AZA) at a dose of 2.0-2.5 mg/kg/day. Level 3: Infliximab 5 mg/kg at Weeks 0, 2, and 6 and every 8 weeks thereafter.
The invention discloses an application of a plukenetia volubilis linneo shell extract in preparing a blood pressure lowering medicine. The extraction method of the embelia nasuta shell extract comprises the following steps: pulverizing Mexican apple shell, adding solvent, decocting, leaching, filtering extractive solution, and concentrating to obtain Mexican apple shell extract. The invention adopts natural plant extracts, and avoids toxic and side effects of western medicines such as captopril and the like on human bodies. The extraction method is simple and feasible, and the mode is flexible. The calamus bungeana shell extract is used for carrying out rat gavage test, and research results show that the calamus bungeana shell extract has a remarkable blood pressure reducing effect, and the calamus bungeana shell extract is deduced to contain functional components for reducing blood pressure. The plukenetia volubilis linneo extract belongs to plant extracts, has stable and mild effects, has no obvious toxic or side effect, and avoids the defect that the traditional western medicine aggravates the sequelae of diabetes while playing the role of lowering blood pressure.
The prioritization of research topics in the health domain is a critical step toward channelling efforts and resources into areas that have received less attention. The objective of this study is to evaluate the implementation of research priorities determined at the national level within Iran for the period spanning five years between 2009 and 2013. We extracted the required data from the Iranian Registry of Clinical Trials (IRCT) website. Then we conducted a matching process between the titles of trials registered in the IRCT until December 3rd, 2013, and the list of national health research priorities in the domains of communicable and non-communicable diseases. The latter was compiled and regulated by the Research and Technology Deputy of the Ministry of Health since 2008. Out of the total 5,049 clinical trials registered in IRCT, 92.3% were carried out within the domain of non-communicable diseases, while 6.1% pertained to the field of communicable diseases and the remaining 1.3% in other fields. 56.4% of the clinical trials conducted in the field of communicable diseases and 32.8% of those conducted in the field of non-communicable diseases were consistent with the research priorities determined in these two fields. During the five-year period of the prioritization goal, there was no significant improvement in adherence to the list of priorities compared to the previous five-year period. Furthermore, certain priorities were neglected within both areas during these periods. It is possible to evaluate the effectiveness of research prioritization using the data obtained from the registration centers of clinical trials. Our study has revealed that the list of priorities has not garnered adequate attention from the research community within the country. Hence, remedial measures are imperative to ensure the priorities are given more attention after publication.
PURPOSE:To obtain the titled antigen (CRA), by crushing and homogenizing the erythrocyte infected with plasmodium, dissolving the precipitate component of the above homogenized erythrocyte with a solubilization agent, and separating a glycoprotein bonding to lectin which bonds specifically with terminal mannose, from the supernatant. CONSTITUTION:Erythrocyte infected with plasmodium (e.g. human plasmodium such as Plasmodium falciparum, rodent plasmodium such as Plasmodium berghei, etc.) is crushed and homogenized e.g. by homogenation process, ultrasonic irradiation, etc. The resultant precipitate component is dissolved with a solubilization agent (e.g. a nonionic surface active agent such as digitonin, urea, etc.), and the glycoprotein bonding to lectin which bonds specifically with terminal mannose is separated from the supernatant component to obtain the objective CRA. The CRA concentration in a malaria vaccine is preferably 0.01-10mug/ml as sugar, and its dose is preferably 1ng/kg/day-100mug/kg/day in 1 - several divided doses.
Disclosed is an isolated polypeptide comprising an amino acid sequence substantially as shown in SEQ ID NO:2, or substantially similar to an amino acid sequence encoded by a nucleotide sequence in a plasmid having all the identifying characteristics of Deposit No. FERM BP-6129. Also disclosed is an isolated polynucleotide substantially as shown in SEQ ID NO:1, or substantially similar to a nucleotide sequence contained in a plasmid having all of the identifying characteristics of Deposit No. FERM BP-6129. Further disclosed is an expression system comprising the above polynucleotide. Further disclosed is a composition comprising the above polypeptide.
The development of atrial fibrillation (AF) is a highly complex, multifactorial process involving pathophysiologic mechanisms, molecular pathway mechanisms and numerous genetic abnormalities. The pathophysiologic mechanisms including altered ion channels, abnormalities of the autonomic nervous system, inflammation, and abnormalities in Ca2 + handling. Molecular pathway mechanisms including, but not limited to, renin-angiotensin-aldosterone (RAAS), transforming growth factor-β (TGF-β), oxidative stress (OS). Although in clinical practice, the distinction between types of AF such as paroxysmal and persistent determines the choice of treatment options. However, it is the pathophysiologic alterations present in AF that truly determine the success of AF treatment and prognosis, but even more so the molecular mechanisms and genetic alterations that lie behind them. One tiny clue reveals the general trend, and small beginnings show how things will develop. This article will organize the development of these mechanisms and their interactions in recent years.
Breast cancer is a tumor with high tumor heterogeneity, and treatment outcomes vary significantly across different molecular subtypes. In recent years, the emergence of novel treatment methods has significantly improved the overall survival and progression-free survival of patients with early-stage, especially metastatic tumors. However, a portion of patients with locally advanced breast cancer (LABC) still have poor prognoses. As early as the 1970s, preoperative radiotherapy was applied to locally advanced breast cancer to increase resectability, but due to limitations in radiotherapy techniques and other factors, preoperative radiotherapy increased the incidence of acute toxic reactions and postoperative complications. Compared to traditional postoperative radiotherapy, neoadjuvant radiotherapy has several theoretical advantages, such as more precise tumor target localization, optimization of breast reconstruction radiotherapy strategies, increased tumor downstaging to improve breast-conserving surgery opportunities, and improved pathological complete response rates, potentially eliminating the need for breast surgery. With the advent of the era of precision radiotherapy, modern radiotherapy technologies have provided solutions to reduce the acute toxic reactions associated with preoperative radiotherapy. This study focuses on preoperative treatment modalities for luminal-type locally advanced breast cancer. It aims to compare the pCR rate, breast-conserving surgery (BCS) rate, progression-free survival (PFS), and treatment-related side effects between preoperative neoadjuvant chemotherapy and preoperative neoadjuvant SBRT combined with chemotherapy in these patients. The goal is to provide new strategic options for the preoperative treatment of luminal-type locally advanced breast cancer.
The present invention provides for compositions or formulations including a curcuminoid and at least one of resveratrol, resveratrol derivative, catechin, or catechin derivative. The present invention also provides for a method of treating any disease where uncontrolled cellular proliferation occurs, such as cancers. In particular, the present invention provides a method for treating cervical cancer and precancerous cervical lesions. The present invention also provides methods to treat viral infections. The disclosed compositions or formulations are biologically more active demonstrating strong synergy, functions to activate multiple novel genes. The disclosure further shows that the composition increases cellular uptake of curcumin and are able to stabilize curcumin in an aqueous environment. All these enhanced properties are accomplished by a composition or formulation that is much simpler to manufacture and lower in cost.
SCOPE: Curcumin (Cur), with diverse pharmacological properties, shows anti-obesity, immunomodulatory, and anti-inflammatory effects. Its role in ulcerative colitis complicated by obesity remains unclear.
METHODS AND RESULTS: Here, colitis is induced in obese mice using dextran sulfate sodium (DSS), followed by administration of Cur at a dosage of 100 mg kg-1 for 14 days. Cur effectively alleviates DSS-induced colitis in obese mice, accompanied by an increase in body weight and survival rate, reduction in disease activity index, elongation of the colon, decrease in colonic weight, and improvements in ulcer formation and inflammatory cell infiltration in colonic tissues. Additionally, Cur effectively improves lipid metabolism and the composition of the gut microbiota, and enhances mucosal integrity and boosts anti-oxidative stress capacity in obese mice with colitis. Importantly, Cur is effective in improving the homeostasis of memory T cells in obese mice with colitis. Furthermore, Cur regulates inflammatory cytokines expression and inhibits activation of the JAK2/STAT signaling pathway in colonic tissues of obese mice with colitis.
CONCLUSIONS: Cur alleviates colitis in obese mice through a comprehensive mechanism that improves lipid metabolism, modulates gut microbiota composition, enhances mucosal integrity and anti-oxidative stress, balances memory T cell populations, regulates inflammatory cytokines, and suppresses the JAK2/STAT signaling pathway.
FIELD: medicine, medicinal industry. SUBSTANCE: invention relates to method of preparing substance from poultry bursa of Fabricius eliciting immunostimulating activity. Raw is subjected for three-fold freezing at minus 40 C alternating with thawing out followed by homogenization. Homogenate is poured with 0.1 N acetic acid solution and phenylmethylsulfonylfluoride is added in concentration 0.1 mM. Extraction is carried out for 30-60 min, extract is filtered off, centrifuged and cooled acetone is added to filtrate for precipitate formation. Precipitate is filtered off, washed out with pure acetone and dried. Obtained powder is dissolved in 0.1 N acetic acid, solution is centrifuged, supernatant is subjected for gel-filtration on Toyopearl HW-40 and fractions of molecular mass from 300 to 3000 Da are collected. Invention provides to enhance immunostimulating activity by 10 times. EFFECT: improved method of preparing, enhanced activity, decreased therapeutical dose and risk of adverse effects. 9 tbl
Ketamine (ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland)) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered. Infusions will be discontinued by the Anaesthetist if there are persisting haemodynamic changes (i.e. heart rate \>110/minute or systolic/diastolic blood pressure (BP) \>180/100 or \>20% increase above pre-infusion BP for more than 15 minutes) that do not respond to beta-blocker therapy.
This group of patients share an address with target high-risk patients (in arms 1-4). This group does not receive an intervention but is monitored for spillover effects of the intervention.
All subjects participating in the clinical trial were monitored for inhibitory and non-inhibitory antibodies to factor IX and antibodies for CHO proteins at the following time points; pre-infusion, after the first 5 exposure days, and then every 3 months thereafter.

No subjects in IXINITY clinical trials developed inhibitors to factor IX, including 55 subjects with more than 50 exposure days and 45 of those subjects with more than 100 exposure days. Non-inhibitory factor IX binding antibodies were detected in 30% (23/77) of subjects, including 5 subjects positive at baseline. In three of the subjects, the non-inhibitory factor IX antibodies were persistent, while in the remainder the antibodies were sporadic and non-persistent. No clinical adverse findings related to non-inhibitory factor IX antibody formation were identified. Detection of non-inhibitory antibodies against factor IX has been reported following administration of other factor IX products. The clinical significance of this finding is unknown.

In IXINITY clinical trials, 29% (20/68) of subjects tested positive for antibodies against CHO cell proteins. No clinical adverse findings were associated with these antibodies. Reports have been published of sporadic detection of antibodies against CHO cell proteins in subjects treated with other recombinant coagulation factor products produced in CHO cells, as well as in non-hemophilic subjects (2). The clinical significance of this is unknown. The manufacturing process for IXINITY was modified to include an additional step to ensure increased clearance of CHO proteins to address the anti-CHO protein response seen in clinical trials. The anti-CHO protein response status of the clinical trial subjects who transitioned to the modified product (n = 17) remained negative (n = 10), stable/nonspecific assay binding (n = 5), or declined (n = 2) after the transition to modified IXINITY for at least 3 months.

The detection of antibody formation is dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection and concomitant medications. For these reasons, comparisons of the incidence of antibodies to IXINITY with the incidence of antibodies to other products may be misleading.
PROBLEM TO BE SOLVED: To obtain an azithromycin dihydrate thermodynamically stable and useful as a medicine in a high yield by adding a base to an aqueous solution of azithromycin using a specific solvent. SOLUTION: This azithromycin dihydrate is obtained by adding a base (preferably sodium hydroxide) to an aqueous solution of azithromycin having a pH of 1-5 and containing acetone. Preferably, the aqueous solution is formed by dissolving azithromycin in acidified water (preferably water adjusted with dilute aqueous solution of hydrochloric acid) having a pH of 1-5 and adding acetone. Preferably, the aqueous solution contains water of 3-7 volume times of a weight of azithromycin. Preferably, the weight ratio of (acetone/water) in the aqueous solution is (7/3)-(3/7). A suspension in the reagent of the resultant crystallized azithromycin is stirred at a temp. of 0-25 deg.C for 6-30 hrs to obtain the objective azithromycin dihydrate having high purity in a high yield.
Streptococcus pneumoniae can cause mortality in infant, elderly, and immunocompromised individuals owing to invasion of bacteria to the lungs, the brain, and the blood. In building strategies against invasive infections, it is important to achieve greater understanding of how the pneumococci are able to survive in the host. Toll-like receptors (TLRs), critically important components in the innate immune system, have roles in various stages of the development of infectious diseases. Endosomal TLRs recognize nucleic acids of the pathogen, but the impact on the pneumococcal diseases of immune responses from signaling them remains unclear. To investigate their role in nasal colonization and invasive disease with/without influenza co-infection, we established a mouse model of invasive pneumococcal diseases directly developing from nasal colonization. TLR9 KO mice had bacteremia more frequently than wildtype in the pneumococcal mono-infection model, while the occurrence of bacteremia was higher among TLR3 KO mice after infection with influenza in advance of pneumococcal inoculation. All TLR KO strains showed poorer survival than wildtype after the mice had bacteremia. The specific and protective role of TLR3 and TLR9 was shown in developing bacteremia with/without influenza co-infection respectively, and all nucleic sensing TLRs would contribute equally to protecting sepsis after bacteremia.
Embodiments disclosed herein convey scanner devices and methods for identifying and storing information emitted by implanted medical devices. In some embodiments, the scanner device includes at least one display, input device, and transceiver all communicatively coupled via at least one control circuit. The control circuit is configured to transmit, via the transceiver, a first interrogating signal to a medical device implanted within a person. In response to the first interrogating signal, the control circuit is configured to receive, via the transceiver, a first response signal from the medical device, the first response signal comprising an identifying information associated with one or more of the medical device and the person. The control circuit is configured to convey, via the display, the identifying information. The input device is configured to allow a user to control an operation of the scanner device.
FIELD: medicine, pharmacy. SUBSTANCE: pharmaceutical composition comprises therapeutically effective dose of amiodarone hydrochloride as an active substance and the following special additions: starch, microcrystalline cellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, stearic acid or its salts and aerosil taken in the definite ratio of indicated components. The composition is made as a tablet. The composition comprises small amount of special additions, tablets release an active substance easily that provides its high bioavailability. Tablets satisfy all requirements of the State Pharmacopoeia of XI Edition. EFFECT: valuable medicinal and pharmaceutical properties of composition. 6 cl, 1 tbl, 3 ex
In Group P (PTI): Single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given on completion of PCNL by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position). Then the surgical wound and intervention site will be covered with an occlusive dressing.